A detailed history of Alpha Centric Advisors LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Alpha Centric Advisors LLC holds 16,500 shares of VKTX stock, worth $1.06 Million. This represents 0.72% of its overall portfolio holdings.

Number of Shares
16,500
Previous 18,000 8.33%
Holding current value
$1.06 Million
Previous $1.48 Million 40.79%
% of portfolio
0.72%
Previous 1.02%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024

SELL
$47.39 - $80.2 $71,085 - $120,300
-1,500 Reduced 8.33%
16,500 $874,000
Q1 2024

Apr 24, 2024

BUY
$17.4 - $94.5 $313,200 - $1.7 Million
18,000 New
18,000 $1.48 Million
Q3 2023

Nov 13, 2023

BUY
$10.92 - $16.0 $655,200 - $960,000
60,000 New
60,000 $664,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.94B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Alpha Centric Advisors LLC Portfolio

Follow Alpha Centric Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Centric Advisors LLC with notifications on news.